《新股消息》內地私人牙科服務商「美皓醫療」申請主板上市
美皓醫療集團向聯交所提交主板上市申請,聯席保薦人為創陞融資及國金證券(香港)。
初步招股文件顯示,根據市場調研機構數據,以2021年收入計集團為溫州最大私人牙科服務提供商,於當地民營及整個牙科服務市場的市場份額分別約為25.2%及13.2%。
美皓醫療主要提供綜合牙科服務,涵蓋口腔綜合治療科、口腔修復科、種植牙科及牙齒正畸科四個牙科領域,目前擁有及營運由5家位於溫州的民營牙科醫院所組成的網絡。截止今年5月30日止五個月,公司收入按年增長36.1%至4,685.8萬元人民幣,純利則增長6.5%至851.8萬元人民幣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.